{
  "guideline": {
    "id": "PA166182810",
    "name": "Annotation of DPWG Guideline for flucloxacillin and HLA-B",
    "source": "DPWG",
    "version": 13,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182810",
    "relatedChemicals": [
      {
        "id": "PA164781042",
        "name": "flucloxacillin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299097",
      "name": "Recommendation PA166299097",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA164781042",
          "name": "flucloxacillin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061460,
        "html": "<ol>\n<li>Regularly monitor the patientâ€™s liver function</li>\n<li>Choose an alternative if liver enzymes and/or bilirubin levels are elevated</li>\n</ol>\n"
      },
      "implications": [
        "HLA-B*57:01-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals)."
      ],
      "lookupKey": {
        "HLA-B": "*57:01 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [],
  "version": "2024-03-25-16-13"
}